Power Law company profile

Ocular Therapeutix

Biotech & Life Sciences · Bedford, United States · Founded 2006 · IPO 2014 Unicorn

Biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye

Valuation

$1.38B

Market cap · May/2026

Revenue

$52M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $1B+ revenueColt · Power Law growth-stage

Investors

15 investors on Ocular Therapeutix's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 15 investors entered at this stage

SV Health Investors

Opaleye Management

Perceptive Advisors

Ascension

TCGX

Great Point Partners

Venrock Healthcare Capital Partners

Deep Track Capital

Surveyor Capital

Versant Ventures

Polaris Partners

Baxter International

Ascension Ventures

Logos Capital

Acuta Capital Partners

Global footprint

Where Ocular Therapeutix has talent and traffic

Workforce by country

🇺🇸 United States · Bedford HQ

Book a demo for the full country breakdown

Web traffic by country

18K monthly visits
across markets

🇺🇸 United States59.4%

🇯🇵 Japan10.6%

🇬🇧 United Kingdom10.6%

🇫🇷 France10%

🇮🇳 India8.3%

Top 5 markets shown

Market sentiment

What the market is saying about Ocular Therapeutix

An AI-synthesized read of the highest-engagement posts about Ocular Therapeutix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ocular Therapeutix on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles